# Cardinal Health Inc: Form 10-Q for the period ended Mar 31, 2025

- Company: [Cardinal Health Inc](/companies/cah.md) (CIK 721371)
- Form: 10-Q
- Filed: 2025-05-01
- Accepted by EDGAR: May 1, 2025, 08:53 ET
- Period: 2025-03-31
- Accession: 0000721371-25-000038
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/721371/000072137125000038/cah-20250331.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/721371/000072137125000038/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2025-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2025-01-01 to 2025-03-31 | $54.88bn | us-gaap:Revenues |
| Revenue | 9 months, 2024-07-01 to 2025-03-31 | $162.42bn | us-gaap:Revenues |
| Cost of revenue | 3 months, 2025-01-01 to 2025-03-31 | $52.76bn | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 9 months, 2024-07-01 to 2025-03-31 | $156.45bn | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2025-01-01 to 2025-03-31 | $2.12bn | us-gaap:GrossProfit |
| Gross profit | 9 months, 2024-07-01 to 2025-03-31 | $5.97bn | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2025-01-01 to 2025-03-31 | $1.31bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2024-07-01 to 2025-03-31 | $3.90bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2025-01-01 to 2025-03-31 | $730.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2024-07-01 to 2025-03-31 | $1.85bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2025-01-01 to 2025-03-31 | $74.0m | us-gaap:InterestExpense |
| Interest expense | 9 months, 2024-07-01 to 2025-03-31 | $141.0m | us-gaap:InterestExpense |
| Income tax | 3 months, 2025-01-01 to 2025-03-31 | $157.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2024-07-01 to 2025-03-31 | $391.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2025-01-01 to 2025-03-31 | $506.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2024-07-01 to 2025-03-31 | $1.32bn | us-gaap:NetIncomeLoss |
| Diluted shares (weighted) | 3 months, 2025-01-01 to 2025-03-31 | 241,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2024-07-01 to 2025-03-31 | 243,000,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months, 2024-07-01 to 2025-03-31 | $870.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months, 2024-07-01 to 2025-03-31 | $315.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months, 2024-07-01 to 2025-03-31 | $374.0m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 9 months, 2024-07-01 to 2025-03-31 | $765.0m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2025-03-31 | $3.33bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2025-03-31 | $34.59bn | us-gaap:AssetsCurrent |
| Total assets | at 2025-03-31 | $49.87bn | us-gaap:Assets |
| Current liabilities | at 2025-03-31 | $36.66bn | us-gaap:LiabilitiesCurrent |
| Shareholders' equity | at 2025-03-31 | −$2.95bn | us-gaap:StockholdersEquity |

## Sections

No standard item headings were found in this filing’s main document, so no sections were extracted. Read the original on sec.gov. https://www.sec.gov/Archives/edgar/data/721371/000072137125000038/cah-20250331.htm

Filed May 1, 2025.
Source: SEC EDGAR, the filing index for accession 0000721371-25-000038. Last ingested by Listed: Nov 5, 2026, 12:30 ET. No prices; not investment advice.
